tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Neurogene’s NGN-401 Gains Favorable Buy Rating Amid Promising Trial Design and Strong Safety Profile
PremiumRatingsNeurogene’s NGN-401 Gains Favorable Buy Rating Amid Promising Trial Design and Strong Safety Profile
2M ago
Neurogene Inc. Reports Increased Losses Amid R&D Focus
Premium
Company Announcements
Neurogene Inc. Reports Increased Losses Amid R&D Focus
2M ago
Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome
Premium
Company Announcements
Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome
2M ago
Promising Advancements in Neurogene’s Gene Therapy for Rett Syndrome Drive Buy Rating
PremiumRatingsPromising Advancements in Neurogene’s Gene Therapy for Rett Syndrome Drive Buy Rating
3M ago
Neurogene Announces Embolden Trial Design for Rett Syndrome
Premium
Company Announcements
Neurogene Announces Embolden Trial Design for Rett Syndrome
3M ago
Neurogene says on track to share updated clinical efficacy and safety data
Premium
The Fly
Neurogene says on track to share updated clinical efficacy and safety data
3M ago
Neurogene price target raised to $26 from $22 at BMO Capital
PremiumThe FlyNeurogene price target raised to $26 from $22 at BMO Capital
4M ago
Neurogene Highlights Gene Therapy Advancements in New Update
Premium
Company Announcements
Neurogene Highlights Gene Therapy Advancements in New Update
4M ago
Neurogene Reports Q1 2025 Financial Progress and Updates
Premium
Company Announcements
Neurogene Reports Q1 2025 Financial Progress and Updates
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100